Valerie Kantro, BA

Molecular Laboratory Manager
JMI Laboratories

Disclosure(s): AbbVie: Grant/Research Support; GSK: Grant/Research Support; Melinta: Grant/Research Support; Shionogi: Grant/Research Support

Poster(s):

• 126 - Frequency of Carbapenemases in United States Hospitals (2016-2020) and Activity of Meropenem-Vaborbactam and Comparator Agents Tested Against These Isolates
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 641 - Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019-2020)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 642 - In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020-2021)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 643 - Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020-2021)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 664 - Increase in the Occurrence of Carbapenem-Resistant Enterobacterales (CRE) in United States (US) Hospitals from 2019 to 2021 and Activity of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations Against These Isolates
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1685 - Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019-2021)
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET